The observed associations between ER status, survival and exposure to ovarian hormones may relate to the tissue specificity of cancers in BRCA2 mutation carriers; mutation carriers have dramatic increases in susceptibility to both female breast and ovarian cancer, and breast cancer in males. This evidence concerns the gene BRCA2 and breast cancer.